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therapeutic testing by providing greater
resolution between normal and dystro-
phic muscle function (Sacco et al., 2010;
Chandrasekharan et al., 2010). For
example, a variety of structurally distinct
microdystrophins (miniaturized versions
of dystrophin that can be efficiently deliv-
ered to dystrophic muscles using ad-
enoassociated viral vectors) are being
tested for use in gene therapy for DMD
(Muir and Chamberlain, 2009). However,
it can be challenging to identify the
constructs that work best in ameliorating
the relatively mild pathophysiology of
mousemdxmutantmuscles. The stronger
phenotype of the mdx/mTR double-
mutant mice provides a better back-
ground for testing therapies. This issue
is significant because even subtle func-
tional changes in mdx muscle function
could translate into significant quality of
life issues for patients. Similar arguments
can be made for testing almost all types
of experimental DMD therapies.
One limitation of the new mdx/mTR
mouse model is the somewhat elaborate1042 Cell 143, December 23, 2010 ª2010 Elsbreeding scheme required to achieve the
desired genotype. Given the significant
therapeutic advances achieved using the
currentmdxmodels, it should be possible
to perform initial or routine testing in the
standard mdx strains and use the more
severely affected double-mutant strains
for secondary and follow-up testing.
Nevertheless, the increased power of
analysis afforded by the newer mutations
may reduce the number of large animal
model studies needed for preclinical
testing of DMD therapeutics and thereby
accelerate thedevelopment of a treatment
for DMD.ACKNOWLEDGMENTS
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Two papers in this issue of Cell (Paradis-Bleau et al., 2010 and Typas et al., 2010) report that the
lipoproteins LpoA and LpoB are required for the synthesis of cell walls in Escherichia coli. Attached
to the bacterial outer membrane, these new cell wall components regulate penicillin-binding
proteins located at the inner membrane.Cell walls protect bacteria against osmotic
lysis. In Gram-negative bacteria, this en-
closingenvelopeconsistsof acytoplasmic
membrane surrounded by an outer
membrane. Sandwiched between the
twomembranes is thepeptidoglycanpoly-
mer, the rigid scaffolding that gives the
wall its strength. Peptidoglycan consistsof repeating linear polymers of N-acetyl-
glucosamine and N-acetylmuramic acid
linked together via short oligopeptide
chains. Because the enzymes that synthe-
size peptidoglycan are the targets of one
of the most important classes of antibi-
otics, the b-lactams, there is great interest
in understanding their activities and regu-lation. In this issue of Cell, two groups
(Paradis-Bleau et al., 2010; Typas et al.,
2010) identify new components of the cell
wall synthetic machinery in E. coli, adding
unexpected complexity to a process that
we thought we understood fairly well.
The final stage of peptidoglycan
synthesis depends on the high molecular
Figure 1. New Outer-Membrane Lipoproteins in E. coli
High molecular weight penicillin-binding proteins (PBP1a and PBP1b) synthesize peptidoglycan in the
bacterial cell wall. They are tethered to the outer face of the inner membrane. Paradis-Bleau et al.
(2010) and Typas et al. (2010) have discovered two new membrane proteins in E. coli, the lipoproteins
LpoA and LpoB, which are found at the outer membrane and enhance the activity of penicillin-binding
proteins. Peptidoglycan, a polymer that gives the bacterial wall rigidity, is depicted as a dashed line,
but its exact location in relation to periplasmic proteins is not known.
(A) The PBP1a-LpoA complex synthesizes peptidoglycan, perhaps mainly in the cylindrical side wall
between the cell poles.
(B) The PBP1b-LpoB complex also synthesizes peptidoglycan in the side wall but can also replace the
Tol-Pal invagination system during cell division.
(C) When artificially tethered to the inner membrane, LpoB can activate PBP 1b but can no longer promote
invagination in the absence of Tol-Pal.
(D) LpoA tethered to the inner membrane can no longer activate PBP 1a.weight penicillin-binding proteins (PBPs),
which polymerize disaccharide precursors
into glycan chains and then covalently
crosslink the chains to form mature pepti-
doglycan (Ho¨ltje, 1998; Margolin, 2009).
In Gram-negative bacteria, penicillin-
binding proteins are anchored to the outer
face of the cytoplasmic (inner) membrane
and synthesize peptidoglycan in the peri-
plasmicspacebetween the innerandouter
membranes (Figure 1). Studies thus far
have suggested that penicillin-binding
proteins are constitutively active and
largely unregulated, though other proteins
may dictate their cellular position (Margo-
lin, 2009; Pichoff and Lutkenhaus, 2007).
Now, Paradis-Bleau et al. and Typas
et al. find that, in E. coli (a Gram-negative
bacterium), the two main high molecular
weight penicillin-binding proteins, PBP
1a and PBP 1b, are each activated by
specific outer-membrane lipoproteins,
LpoA and LpoB, respectively (Figure 1A).
Although these lipoproteins are not
homologous to one another, they appear
to perform similar functions because
bacterial survival requires the presence
and activity of at least one PBP-Lpo pair.
In vitro, Typas et al. find that PBP 1a and
PBP 1b can synthesize peptidoglycanbut that LpoA and LpoB enhance their
activities. However, Paradis-Bleau et al.
find that in vivo overproduction of either
PBP 1a or PBP 1b does not rescue
defects caused by deleting an Lpo
protein, suggesting that the lipoproteins
may be required for enzymatic function
and do not merely enhance PBP activity.
A potential explanation for this apparent
discrepancymay be that, in vivo, peptido-
glycan is not distributed correctly in the
absence of the Lpo lipoproteins. Alterna-
tively, the in vitro system may artificially
activate the PBPs, or perhaps a negative
regulator that exists in vivo necessitates
lipoprotein involvement.
The PBP1b-LpoB complex performs at
least one function that PBP1a-LpoA
cannot. During bacterial cell division, all
three envelope components constrict as
a unit as the division septum invaginates
to form the poles of two new daughter
cells. This process requires tethering of
the outer membrane to the underlying
peptidoglycan layer and to the inner
membrane via a group of proteins known
as the Tol-Pal system (Gerding et al.,
2007). Although E. coli cells survive the
loss of any one of these proteins (i.e.,
PBP 1a, PBP 1b, LpoA, LpoB, or Tol-Pal),Cell 143, DeTypas et al. find that the cells lyse when
both the Tol-Pal and the PBP1b-LpoB
complexes are deleted. These findings
suggest that PBP1b-LpoB, but not
PBP1a-LpoA, can replace the tethering
function of Tol-Pal during cell division
(Figure 1B). However, the functional
significance of this finding is unclear
because E. coli cells still grow and divide
in the absence of PBP1b-LpoB, indicating
that PBP1a-LpoA can also synthesize
peptidoglycan during septation. Never-
theless, the results suggest that bacteria
without a Tol-Pal system may employ
PBP1b-LpoB analogs to tether the outer
membrane to the septum.
To determine whether the functions of
the Lpo proteins depend on their localiza-
tion to the outer membrane, both Paradis-
Bleau et al. and Typas et al. create Lpo
fusions that localize to the inner—instead
of outer—membrane (Figures 1C and 1D).
In this configuration, LpoA does not acti-
vate PBP 1a (Figure 1D), suggesting that
a productive pairing requires another
outer-membrane component or that
the inner-membrane location prevents
a proper three-dimensional interaction.
Surprisingly, LpoB can still activate PBP
1b (Figure 1C), indicating that the
PBP1b-LpoB interaction is less depen-
dent on exact subcellular localization.
However, as expected given the tethering
role of the Tol-Pal proteins, the inner-
membrane PBP1b-LpoB complex no
longer complements the defect of
a mutant lacking the Tol-Pal system
(Figure 1C).
Although all bacteria that synthesize
peptidoglycan express bifunctional
PBPs that polymerize and then crosslink
glycan chains, the specific PBP-lipopro-
tein combinations described in the
current papers are restricted to the g-pro-
teobacteria lineage of Gram-negative
bacteria, and obvious LpoB homologs
are restricted further to the Enterobacter-
iaceae, a bacterial subgroup commonly
found in vertebrate intestines. Why is the
PBP-Lpo combination not more wide-
spread? One possibility is that the
Enterobacteriaceae, by virtue of their
physiological niche or for other unknown
reasons, need this extra device to regu-
late peptidoglycan synthesis. Another
possibility is that other bacteria use
accessory factors unrelated to the Lpo
proteins to regulate peptidoglycancember 23, 2010 ª2010 Elsevier Inc. 1043
synthesis. Either way, the results suggest
that peptidoglycan synthesis is subject to
external controls that have heretofore
escaped detection, and it is thus worth
investigating how such regulation may
be accomplished in other organisms.
Why are these results surprising? First,
LpoA and LpoB are the first regulators of
the high molecular weight penicillin-
binding proteins. It is likely that such regu-
lation exists to meet some physiological
need, which awaits discovery. Second, it
is not only their existence but their loca-
tion that is surprising. The fact that the
lipoproteins are tethered to the outer
membrane means they must cross the
peptidoglycan layer to make contact
with the penicillin-binding proteins, which
are tethered to the inner membrane
(Figure 1). Paradis-Bleau et al. speculate
that the lipoproteins may guide peptido-1044 Cell 143, December 23, 2010 ª2010 Elsglycan synthesis along defined tracks.
Typas et al. suggest that the lipoproteins
may control the rate or location of new
synthesis by reaching through holes in
the peptidoglycan to contact and activate
the PBPs, which are tethered to the inner
membrane on the other side of the wall.
There are, no doubt, other possibilities.
Finally, the reports raise many ques-
tions. Do Gram-positive bacteria, which
don’t have an outer membrane but have
a much thicker peptidoglycan layer, also
express proteins that regulate penicillin-
binding proteins? And if so, where in the
cell are these proteins located? Can cell
wall synthesis be reconstituted in vitro?
Are there any other important cell wall
agents that we don’t know about, and
might any of these new components
serve as targets for antibiotics? Future
studies to address these and other ques-evier Inc.tions should reveal whole new vistas of
the bacterial cell wall.REFERENCES
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Two key events inWnt signal transduction, receptor endocytosis and inactivation of Glycogen Syn-
thase Kinase 3 (GSK3), remain incompletely understood. Taelman et al. (2010) discover that Wnt
signaling inactivates GSK3 by sequestering the enzyme in multivesicular bodies, thus linking these
two events and providing a new framework for understanding Wnt signaling.Cell-cell signaling via thecanonicalWnt/b-
catenin pathway underlies numerous
processes in development, and its mis-
regulation is associated with human
disease, notably cancer. At the heart of
canonical Wnt signaling is derepression
of the cytoplasmic protein b-catenin. In
the absence of Wnt signaling, b-catenin
is rapidly targeted for degradation due to
phosphorylation by Glycogen Synthase
Kinase 3 (GSK3). In the presence of Wntsignaling, the phosphorylation of b-cate-
nin by GSK3 is suppressed, and b-catenin
becomes dephosphorylated and stabi-
lized and enters the nucleus to regulate
Wnt target gene transcription. Exactly
how Wnt signaling suppresses GSK3
activity remains one of the unsolved
mysteries in Wnt signaling. Another un-
solved question inWnt signaling concerns
the requirement for receptor endocytosis.
The work of Taelman et al. (2010) nowelegantly provides an answer to both of
these open questions with the discovery
that Wnt signaling triggers GSK3 seques-
tration in multivesicular bodies, a late
endocytic compartment that harbors in-
tralumenal vesicles.
Wnt/b-catenin signaling is mediated by
high-affinity Wnt receptors of the seven-
pass transmembrane Frizzled family and
a coreceptor, the low-density lipoprotein
(LDL)-receptor related protein 6 (LRP6).
